TAKHZYRO is a medicine that is used to prevent attacks of hereditary angioedema (HAE) in adults and adolescents (12 years and older). TAKHZYRO should not be used to treat an acute HAE attack. In the event of an acute attack, seek medical attention.
Prophylaxis refers to the ongoing routine prevention of HAE attacks.
Prophylaxis does not eliminate the risk completely. You may still have HAE attacks. You and your healthcare team should make a plan to treat attacks on demand despite being on prophylactic therapy.
In HAE, uncontrolled production of a substance called plasma kallikrein occurs. This leads to the release of too much bradykinin in your bloodstream. Too much bradykinin leads to symptoms like swelling and pain.
TAKHZYRO is a type of protein that blocks the activity of plasma kallikrein. This helps to limit the production of bradykinin in your bloodstream and can prevent the swelling associated with HAE.